New paradigm for allosteric drug discovery
Humans have long aspired to imitate things we see in nature – processes and outcomes perfected over billions of years – adapting and evolving to overcome challenges and improve life. Birds inspired airplanes, the brain produced artificial intelligence, and the stars taught us how to create clean energy.
Within every human cell, nature has engineered molecular control mechanisms to correct imbalances caused by stress and disease. And yet, never before have these mechanisms served as the inspiration for medicines. Until now.
HotSpot Therapeutics is leading the way in creating medicines that target unexploited pockets on proteins that are critical to their function - natural hotspots.Learn more about our science
HotSpot Therapeutics’ platform - Smart Allostery™ - is the first that integrates machine learning, structure-function and tailored chemistry to systematically uncover and drug pockets on proteins used to control their function. HotSpot is industrializing the discovery of allosteric medicines, targeting natural hotspots to treat diseases in new ways.Learn more about our Smart Allostery™ platform
In the news
AbbVie offers up to $335M for connection with HotSpot’s preclinical small-molecule program
AbbVie puts up $40M to license a treatment from HotSpot Therapeutics
HotSpot Therapeutics secures $100M to advance allosteric platform
Boston Neighbors Net $256 Million for Treg and Allosteric Therapies
HotSpot Therapeutics snags $100M series C to bring allosteric meds into the clinic
Cancer-Targeting Biotech Startup HotSpot Therapeutics Raises $100M